Loading...

Alexa Fluor® 488 anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_Alx488_090507
C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 488
  • 30-F11_Alx488_090507
    C57BL/6 mouse splenocytes stained with 30-F11 Alexa Fluor® 488
  • 33_Mouse_Spleen_CD169_CD45
    Confocal image of C57BL/6 mouse spleen sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD169 (green) in Cycle 2 and CD45 (blue) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
See Alexa Fluor® 488 spectral data
Cat # Size Price Quantity Check Availability Save
103121 25 µg 81€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103122 100 µg 184€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Gutknecht M, et al. 2017. Nat Commun. 10.1038/s41467-017-00488-6. PubMed
  2. Logan C, Bowen C, and Menko A 2017. Sci Rep. . 10.1038/s41598-017-16456-5. PubMed
  3. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  4. Peng W, et al. 2018. Mol Cell Biol. 38:e00427. PubMed
  5. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  6. Lee EKS, et al. 2018. Cell Host Microbe. 23:121. PubMed
  7. Wu X, et al. 2018. Cell. 172:423. PubMed
  8. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  9. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  10. Dubey LK, et al. 2019. Cell Rep. 27:2442. PubMed
  11. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  12. Kazakevych J, et al. 2019. Sci Rep. 9:10410. PubMed
  13. Wang Y, et al. 2019. Front Cell Infect Microbiol. 9:286. PubMed
  14. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  15. von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed
  16. Kazakevych J, et al. 2020. Genome Biol. 21:64. PubMed
  17. Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed
  18. Giorgetti E, et al. 2020. Cell Reports. 29(6):1539-1554.e7.. PubMed
  19. Pang M, et al. 2009. J Immunol. 182:7001. PubMed
  20. Ferrari G, et al. 2011. Invest Ophthalmol Vis Sci. 52:2532. PubMed
  21. Ye Y, et al. 2011. Am J Physiol Lung Cell Mol Physiol. 300:L216. PubMed
  22. Braun D, et al. 2013. J Biol Chem. 288:2689. PubMed
  23. Khandelwal P, et al. 2013. PLoS One. 8:64193. PubMed
  24. Marko C, et al. 2014. Invest Ophthalmol Vis Sci . 55:291. PubMed
  25. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  26. Kuo P, et al. 2016. J Am Heart Assoc. 5: 002610. PubMed
  27. Ding H, et al. 2016. Nat Commun. 7:11533. PubMed
  28. Denk F, et al. 2016. Cell Rep. 15: 1771-1781. PubMed
  29. Chen I, et al. 2016. Sci Rep. 6:27195. PubMed
  30. Tian F, et al. 2016. Nat Commun. 7:13283. PubMed
  31. Mizbani A, et al. 2016. Development. 143: 4137 - 4148. PubMed
  32. Duarte J, et al. 2016. J Immunol. 197(12):4838-4847. PubMed
  33. Bornes L, et al. 2021. Life Sci Alliance. 4:00. PubMed
  34. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  35. Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed
  36. Masschelein E, et al. 2020. Skelet Muscle. 10:21. PubMed
  37. Burns JC, et al. 2020. eLife. 9:00. PubMed
  38. DeDreu J, et al. 2020. FASEB J. 34:9316. PubMed
  39. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  40. Reed-Geaghan EG, et al. 2020. J Exp Med. 217:00:00. PubMed
  41. Liu X, et al. 2020. Cell Host Microbe. 28(5):683-698.e6. PubMed
  42. Yip HYK, et al. 2020. Molecular Cell. 80(2):279-295.e8. PubMed
  43. Rodriguez AB, et al. 2021. Cell Reports. 36(3):109422. PubMed
  44. Yip HYK, et al. 2021. STAR Protocols. 2(3):100765. PubMed
  45. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  46. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  47. Preda MB, et al. 2021. Cell Death Dis. 12:566. PubMed
  48. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  49. Wara AK, et al. 2020. Cell Rep. 33:108550. PubMed
  50. Steele NG, et al. 2021. Clin Cancer Res. 27:2023. PubMed
  51. Shibad V, et al. 2021. Front Immunol. 12:722451. PubMed
  52. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
  53. Li Q, et al. 2020. Am J Pathol. 190:2453. PubMed
  54. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  55. Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed
  56. Limbad C, et al. 2022. iScience. 25:103848. PubMed
  57. DeDreu J, et al. 2022. FASEB J. 36:e21995. PubMed
  58. Lustgarten Guahmich N, et al. 2020. Angiogenesis. 23:443. PubMed
  59. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  60. Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed
  61. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  62. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  63. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  64. Lasch M, et al. 2020. Front Physiol. 11:576736. PubMed
  65. Hallett JM, et al. 2022. Cell Stem Cell. 29:355. PubMed
  66. Li D, et al. 2022. Commun Biol. 5:271. PubMed
  67. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  68. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  69. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  70. Wemlinger SM, et al. 2022. J Immunol. 208:1566. PubMed
  71. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  72. Frederico B, et al. 2022. Dev Cell. 57:1957. PubMed
  73. Ullah I, et al. 2023. Cell Rep Med. 4:100893. PubMed
  74. Olivares-González L, et al. 2022. Antioxidants (Basel). 12: . PubMed
  75. Gilman KE, et al. 2023. Front Immunol. 13:1045710. PubMed
  76. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  77. Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed
  78. Luff SA, et al. 2022. Nat Cell Biol. 24:616. PubMed
  79. Battis K, et al. 2022. J Neurosci. 42:7673. PubMed
  80. Abdel-Haq R, et al. 2022. Elife. 11:. PubMed
  81. Axelrod ML, et al. 2022. Nature. 611:818. PubMed
  82. Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed
  83. Fan Z, et al. 2023. Angiogenesis. . PubMed
  84. Gilman KE, et al. 2023. Cancers (Basel). 15:. PubMed
  85. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  86. Fixsen BR, et al. 2023. Nat Immunol. . PubMed
RRID
AB_493532 (BioLegend Cat. No. 103121)
AB_493531 (BioLegend Cat. No. 103122)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Go To Top Version: 5    Revision Date: 04/20/2022

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account